PlainBillCongress, translated.Legislation. Context. Public interest.Referred to the House Committee on Energy and Commerce.
Congressional Research Service
No official summary is available in the imported record yet.
People & committees
Rep. McCaul, Michael T. [R-TX-10] · R–TX
Legislative record
A procedural vote is different from passage. Passage in one chamber does not establish enactment. Explore the glossary.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Primary sources
Text links open the official source. We also preserved the text version used in the PlainBill explanation below.
No related bills are listed in this snapshot. This does not establish whether the proposal has appeared in earlier Congresses.
Source last updated: Sep 22, 2026. Consult Congress.gov for the current record.
AI Conversation Starters
Choose a perspective, copy a prompt, and paste it into your preferred AI. Each prompt includes the bill version and available official source links, and asks for counterarguments as well as supporting evidence.
Analyze H.R.10370 as objectively as possible. Explain its main provisions, who would be affected, possible benefits and harms, implementation, exceptions, and uncertainties. Present the strongest arguments for and against it, and identify evidence needed to assess its public impact.
Examine H.R.10370 through a progressive lens, focusing on fairness, access, economic inequality, and effects on vulnerable communities. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and distinguish stated goals from demonstrated outcomes.
Examine H.R.10370 through a conservative lens, focusing on fiscal responsibility, institutional stability, federalism, and the scope of government. Explain potential benefits, costs, and unintended consequences. Consider the strongest counterarguments and any provisions that challenge this perspective.
Examine H.R.10370 through a civil-liberties and limited-government lens. Consider individual rights, privacy, voluntary choice, accountability, and government power. Explain tradeoffs, possible safeguards, and the strongest counterarguments without assuming the proposal is beneficial or harmful.
PlainBill explanation
Based on the full Introduced in House · 2026-09-14 text. This explanation has not received human editorial review. This overview describes the proposal’s major provisions; it does not establish what its real-world effects would be.
The bill would coordinate federal use of artificial intelligence and expand data collection and sharing to support research and care for childhood cancer. Its data initiative would cover people diagnosed as children, adolescents, or young adults, even when their data are collected later in life. It would also require standards for exchanging patient data for use with artificial intelligence across the Department of Health and Human Services. These are proposed requirements, aimed at improving care; the text does not establish that those improvements would occur.
to coordinate Federal efforts to use advanced technologies, including artificial intelligence, to improve the diagnosis, treatment, and prevention of, and the development of cures for, pediatric cancer.
The NCI Director shall carry out the CCDI to collect, generate, standardize, link, and share data with respect to individuals who are diagnosed with cancer as a child, adolescent, or young adult, regardless of the age of the individual on the date such data is collected, regardless of where such individual receives care
The standards finalized under subsection (b) shall be developed for application throughout the Department of Health and Human Services and shall not be limited in application to the CCDI or to the National Cancer Institute.
The President would designate a federal official or executive-branch body as the Coordinator of AI Innovation and notify the specified congressional committees within 30 days after that designation.
The President shall designate an officer or employee of the Federal Government, or an office, council, or commission of the executive branch
The officer, employee, office, council, or commission so designated shall be known as the Coordinator of AI Innovation
Not later than 30 days after making a designation under subsection (a), the President shall notify the appropriate committees of Congress of the designation.
The coordinator would align federal agency activities and data policies affecting childhood cancer research and care, encourage collaboration with patients and other outside participants, and consult with the National Cancer Institute about the Childhood Cancer Data Initiative.
coordinate and align the activities of relevant Federal departments and agencies
interagency coordination and collaboration among Federal and non-Federal entities, such as patients, survivors, families, caregivers, researchers, and entities funding research on pediatric cancer
(3) align Federal data and artificial intelligence policies affecting pediatric cancer research and care; (4) consult with the Director of the National Cancer Institute on matters affecting the CCDI; and (5) support the Federal activities that advance the purposes of this Act, including the activities of the CCDI.
The term CCDI means the initiative known as the Childhood Cancer Data Initiative.
The National Cancer Institute director would run the Childhood Cancer Data Initiative to collect, create, standardize, connect, and share data about people diagnosed with cancer as children, adolescents, or young adults. Coverage would not depend on their age when data are collected or where they receive care. The stated goals include prevention, diagnosis, treatment, quality of life, and health after cancer.
The NCI Director shall carry out the CCDI to collect, generate, standardize, link, and share data with respect to individuals who are diagnosed with cancer as a child, adolescent, or young adult, regardless of the age of the individual on the date such data is collected, regardless of where such individual receives care, in order to improve outcomes for individuals with such cancers, including with respect to prevention, diagnosis, treatment, quality of life, and survivorship.
The term NCI Director means the Director of the National Cancer Institute.
The initiative would have to support studying childhood cancers' molecular features and sharing those results to inform diagnosis and treatment. It would also support generating, analyzing, and sharing data from non-invasive, clinically validated technologies, software, and artificial intelligence tools.
shall support, at a minimum— (A) molecular characterization of pediatric cancers, including through the initiative known as the Molecular Characterization Initiative of the CCDI, and the sharing of the results of such characterization to inform diagnosis and treatment; (B) the generation, analysis, and sharing of data produced by non-invasive clinically validated technologies, software, and artificial intelligence tools, including molecular testing and functional precision medicine approaches, to inform diagnosis and treatment
Required support would also cover data platforms and tools, research data on rare childhood cancers, and combining clinical, research, and population data for additional uses, including through the National Childhood Cancer Registry. The director could support other activities serving the initiative's purposes.
(C) data platforms, catalogs, and tools that enable researchers and clinicians to find, access, integrate, analyze, and share pediatric cancer data, including the network of such platforms and tools known as the CCDI Data Ecosystem; (D) the collection and study of data on pediatric cancers, including rare pediatric cancers; (E) the aggregation and linkage of clinical, research, and population-based data for secondary use, including through the registry known as the National Childhood Cancer Registry; and (F) the development of data standards and infrastructure necessary to carry out subparagraphs (A) through (D); and (2) may support such other activities as the NCI Director determines appropriate to carry out subsection (a).
The Secretary would appoint a director for the Childhood Cancer Data Initiative on the National Cancer Institute director's recommendation. That person would need relevant scientific expertise, lead the initiative and its artificial intelligence work, coordinate with federal and outside partners, and report to the institute's director.
The Secretary, on the recommendation of the NCI Director, shall designate a Director of the Childhood Cancer Data Initiative
(1) be an individual with demonstrated scientific expertise in pediatric oncology, biomedical data science, or a related field; (2) provide scientific and programmatic leadership for the CCDI, including the components described in subsection (b) and the artificial intelligence activities described in section 202; (3) coordinate the activities of the CCDI with other Federal departments and agencies and with non-Federal partners; and (4) report to the NCI Director.
The National Cancer Institute director would support developing and using artificial intelligence for childhood cancer research and care, in coordination with the federal coordinator. Required preparation would include improving the initiative's data tools, combining data from different sources into compatible forms, and developing technical standards.
The NCI Director shall support, in coordination with the Coordinator, the development and application of artificial intelligence to accelerate progress in pediatric cancer research and care, including through the CCDI.
(1) expand and improve the artificial intelligence readiness of the data platforms and tools of the CCDI Data Ecosystem; (2) consolidate and harmonize data from multiple sources to enable such data to be analyzed using artificial intelligence; and (3) develop data standards and technical approaches necessary for the use of artificial intelligence with the data described in paragraphs (1) and (2).
Supported artificial intelligence research would seek better predictions of treatment response, disease progression, and harmful treatment effects. It would also seek new biological indicators useful for diagnosis, predicting disease course, and treatment, and include projects at National Cancer Institute-designated cancer centers.
the NCI Director shall support research on pediatric cancer using artificial intelligence— (1) to improve predictive modeling of patient response, disease progression, and treatment toxicity; (2) to derive novel diagnostic, prognostic, and therapeutic biomarkers from molecular and imaging data; and (3) to carry out research projects, including projects carried out at cancer centers designated by the National Cancer Institute.
The Secretary would support using multiple types of data and artificial intelligence throughout clinical trials for products intended to diagnose, treat, prevent, or cure childhood cancer. This would include trial design, participant recruitment and selection, administration, conduct, and interpretation.
the Secretary shall support the use of multimodal data and artificial intelligence to improve the design, participant recruitment and selection, administration, conduct, and interpretation of clinical trials for medical products intended to diagnose, treat, prevent, or cure pediatric cancer.
The artificial intelligence activities would have to add to, rather than replace, the initiative's required components. The Secretary would make resulting methods, tools, standards, and technical approaches available to other National Cancer Institute programs and federal agencies, and to the public when appropriate.
Activities under this section shall supplement, and not supplant, the components described in section 201(b).
The Secretary shall make methods, tools, data standards, and technical approaches developed under this section available to other programs of the National Cancer Institute, to other Federal departments and agencies, and, as appropriate, to the public.
The Health and Human Services Secretary, acting through the National Coordinator for Health Information Technology, would integrate artificial intelligence into existing work on interoperability—the ability of health information systems to exchange and use data. The stated purpose is to help electronic health records and insurance claims inform private and academic research and trial design, while protecting identifiable health information under the cited privacy regulations.
The Secretary of Health and Human Services, acting through the National Coordinator for Health Information Technology, shall ensure that artificial intelligence is appropriately integrated into interoperability activities carried out under title XXX of the Public Health Service Act (42 U.S.C. 300jj et seq.), in order to improve the potential for electronic health record and claims data to inform private sector and academic research and clinical trial design, while ensuring the privacy of individually identifiable health information in accordance with regulations promulgated under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d–2 note).
Within two years after enactment, the Secretary would have to finalize standards for exchanging patient data for use with artificial intelligence. They would address structured and unstructured data, safe exchanges that comply with privacy requirements, and children's needs, including childhood cancer, as a priority. The standards would be developed for use throughout Health and Human Services, beyond the cancer initiative and National Cancer Institute.
Not later than 2 years after the date of the enactment of this Act, the Secretary, acting through the National Coordinator for Health Information Technology, shall finalize interoperability standards for patient data to be used with artificial intelligence that— (1) appropriately account for structured and unstructured data; (2) enable safe and privacy-compliant exchanges of data; and (3) account for the needs of pediatric patients, including pediatric cancer patients, as a priority use case.
The standards finalized under subsection (b) shall be developed for application throughout the Department of Health and Human Services and shall not be limited in application to the CCDI or to the National Cancer Institute.
The data-sharing work would require consultation with patients, families, health care providers, researchers, and health information technology developers. Officials would work with the patient community on transparency and ways to share data, identify barriers to exchanging children's data, and recommend ways to address them.
(1) consult with the Director, the CCDI Director, patients and their families, health care providers, researchers, and developers of health information technology; (2) coordinate with the patient community to ensure transparency and to establish mechanisms for the sharing of data; and (3) identify existing barriers to pediatric data sharing and interoperability, in coordination with the stakeholder community, and make recommendations to address such barriers.
Within 180 days after enactment, the Health and Human Services Secretary would submit an interim report to the specified congressional committees describing implementation progress, interim findings, and barriers for the department's responsibilities under Title II.
Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services shall submit to the appropriate committees of Congress a report that— (1) describes the progress made in implementing this title; (2) includes any interim findings of the Secretary with respect to that implementation; and (3) identifies any barriers to that implementation.
Annual reports would begin within one year after enactment and continue through fiscal year 2031. They would describe activities, spending, progress on data exchange and privacy, the status of required standards, barriers and recommendations, and outcomes and measures of progress on childhood cancer.
Not later than 1 year after the date of the enactment of this Act, and annually thereafter through fiscal year 2031
(1) a description of the activities carried out under this title, including each component described in section 201(b) and the artificial intelligence activities described in section 202; (2) the amounts expended on such activities; (3) progress on data sharing, interoperability, and privacy protections, including the status of the interoperability standards required under section 203(b); (4) the barriers identified in section 203(d)(3) and the recommendations made to address such barriers; and (5) outcomes and measures of progress with respect to the diagnosis, treatment, prevention, or cure of pediatric cancer.
The committees receiving the required notices and reports would be House Energy and Commerce; House Science, Space, and Technology; Senate Health, Education, Labor, and Pensions; and Senate Commerce, Science, and Transportation. The bill would use an artificial intelligence definition from a separate law rather than reproduce that definition.
The term appropriate committees of Congress means— (A) the Committee on Energy and Commerce of the House of Representatives; (B) the Committee on Science, Space, and Technology of the House of Representatives; (C) the Committee on Health, Education, Labor, and Pensions of the Senate; and (D) the Committee on Commerce, Science, and Transportation of the Senate.
The term artificial intelligence has the meaning given such term in section 238(g) of the John S. McCain National Defense Authorization Act for Fiscal Year 2019 (Public Law 115–232).
All activities under the bill would have to comply with applicable federal and state patient-information privacy laws, including regulations under the Health Insurance Portability and Accountability Act of 1996.
Activities under this Act shall be carried out in a manner consistent with applicable Federal and State laws relating to the privacy of patient information, including the regulations promulgated under section 264(c) of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. 1320d–2 note).
The bill would authorize Congress to provide $100 million for the Childhood Cancer Data Initiative under section 201 in each fiscal year from 2027 through 2031. This is permission for funding through appropriations, not an appropriation that itself supplies the money.
In addition to amounts authorized to be appropriated under subsection (a), there are authorized to be appropriated to carry out section 201 $100,000,000 for each of fiscal years 2027 through 2031.
For the bill's activities outside section 201, it would authorize whatever funding is necessary for each fiscal year from 2027 through 2031, without specifying a dollar amount. This also would require appropriations to supply the money.
There are authorized to be appropriated to carry out this Act, other than section 201, such sums as may be necessary for each of fiscal years 2027 through 2031.
The bill would preserve authority that other federal laws give the Health and Human Services Secretary and the National Cancer Institute director.
Nothing in this Act shall be construed to affect the authority of the Secretary of Health and Human Services or the Director of the National Cancer Institute under any other provision of Federal law.
The supplied official-actions snapshot, updated September 22, 2026, records introduction in the House and referral to the House Committee on Energy and Commerce on September 14, 2026. That snapshot does not establish subsequent legislative action or enactment.
Source snapshot updated 2026-09-22T15:49:43Z. 2026-09-14: Referred to the House Committee on Energy and Commerce. 2026-09-14: Introduced in House
A closer look
Reviewed version: Introduced in House · 2026-09-14. These findings describe provisions and who may benefit; they are not judgments of waste, corruption, or motive.
This review covers the supplied bill text. “None identified” does not rule out provisions in later versions or accompanying reports and disclosures.
Provisions outside the bill’s main subject, or policy changes attached to appropriations.
None identified in the reviewed text
No unrelated provision or policy rider was identified in the complete supplied introduced text. This conclusion applies only to that version and does not establish absence in other versions or accompanying materials.
Spending directed to particular recipients or places outside ordinary competitive or formula-based allocation.
None identified in the reviewed text
No congressionally directed spending for a particular recipient or place meeting the stated earmark criteria was identified in the complete supplied introduced text. This text-only conclusion does not resolve formal earmark status in disclosures or other materials.
Narrow exceptions, exemptions, or preferential treatment that warrant a closer look.
None identified in the reviewed text
No materially narrow carve-out, special exemption, or preferential treatment meeting the stated criteria was identified in the complete supplied introduced text. Ordinary program coverage and administration are not treated as targeted benefits. This conclusion is limited to the supplied version.
Full text preserved for this analysis. Legislative record snapshot: Sep 22, 2026. How PlainBill uses AI